Abstract
Serotonin specific reuptake inhibitor antidepressants (SSRIs) have become the de facto first line treatment in pharmacotherapy of major depression. Albeit SSRIs have the advantage in tolerance and safety over older treatments, their ease of use does not circumvent the major enduring clinical problem of treatment resistant depression (TRD). For TRD in the setting of an SSRI failure recent data supports a range of strategies including switching, either to a second SSRI or out of the class to a non-SSRI antidepressant, or augmentation with the addition of lithium carbonate. Data concerning use of buspirone and pindolol, serotonin 1A receptor partial agonists, as augmentation agents in SSRI failure remains mixed. In contrast venlafaxine continues to look quite promising in TRD.
Keywords
Treatment-resistant depressionVenlafaxineAntidepressantPindololBuspironeSerotonin reuptake inhibitorDepression (economics)MedicineMajor depressive disorderPsychologySerotonin Uptake InhibitorsPharmacotherapyClomipramineReuptake inhibitorFluoxetinePsychiatryMoodSerotoninInternal medicineReceptorAnxiety
Affiliated Institutions
Related Publications
Neuroendocrine Response to L-5-Hydroxytryptophan Challenge in Prepubertal Major Depression
The neuroendocrine response to L-5-hydroxytryptophan was compared in 37 prepubertal children who met the Research Diagnostic Criteria for major depressive disorder with that in ...
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on...
Publication Info
- Year
- 2000
- Type
- article
- Volume
- 13
- Issue
- 1
- Pages
- 93-98
- Citations
- 25
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
25
OpenAlex
Cite This
John P. O’Reardon,
David J. Brunswick,
Jay D. Amsterdam
(2000).
Treatment-resistant depression in the age of serotonin: evolving strategies.
Current Opinion in Psychiatry
, 13
(1)
, 93-98.
https://doi.org/10.1097/00001504-200001000-00016
Identifiers
- DOI
- 10.1097/00001504-200001000-00016